Prolonged survival of a patient with lung cancer after treatment with S-1, a new oral fluoropyrimidine anticancer drug
暂无分享,去创建一个
M. Satouchi | T. Kurata | S. Negoro | Y. Urata | T. Shimada | S. Yoshimura | Y. Takada
[1] Y. Ichinose,et al. S-1 Plus Cisplatin Combination Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[2] N. Izumi,et al. [A case of advanced gastric cancer acquired long-term response two years or more by treatment with oral anticancer drug TS-1]. , 2004, Gan to kagaku ryoho. Cancer & chemotherapy.
[3] H. Nagai,et al. [A case of type 4 gastric cancer with peritoneal dissemination successfully treated over 2 years by alternate-day administration of TS-1]. , 2004, Gan to kagaku ryoho. Cancer & chemotherapy.
[4] Y. Furuta,et al. [Long-term complete response to treatment with TS-1 in a patient with oropharyngeal squamous cell carcinoma]. , 2002, Gan to kagaku ryoho. Cancer & chemotherapy.
[5] S. Kudoh,et al. Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer , 2001, International Journal of Clinical Oncology.
[6] S. Kudoh,et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer , 2001, British Journal of Cancer.
[7] R. Diasio,et al. Clinical implications of dihydropyrimidine dehydrogenase inhibition. , 1999, Oncology.
[8] M. Fukushima,et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. , 1996, Anti-cancer drugs.
[9] A. Fujioka,et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. , 1996, Cancer research.
[10] Handra,et al. COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON–SMALL-CELL LUNG CANCER , 2001 .